Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season

Influenza Clinical Trial

Official title:

Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 ugHA/Strain/0.5mL) in Adult and Elderly Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01649713
• Other study ID #: Fluval AB-H-YL2012
• Secondary ID: 2012-002379-32
• Status: Completed
• Phase: Phase 4
• First received: July 23, 2012
• Last updated: October 11, 2012
• Start date: August 2012
• Est. completion date: September 2012

Study information

• Verified date: October 2012
• Source: Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Hungary: National Institute of Pharmacy
• Study type: Interventional

Clinical Trial Summary

This is a yearly licence tolerability and immunogenicity study of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/strain/0.5mL) in adult and elderly subjects to assess immunogenicity of a single intramuscular injection of Fluval AB suspension for injection, as measured by haemagglutination inhibition (HI) test, and to evaluate safety and tolerability (incidence of adverse events) of a single intramuscular injection of Fluval AB suspension for injection.

Description:

For the 2011-2012 vaccination season the following influenza virus strains were recommended to be included in the influenza vaccines:

• A/California/7/2009(H1N1)-like virus,

• A/Perth/16/2009(H3N2)-like virus,

• B/Brisbane/60/2008-like virus.

For the 2012-2013 season the following strains were recommended (Amended EU Recommendations for the Seasonal Influenza Vaccine Composition for the Season 2012/2013, EMA/CHMP/BWP/140597/2012):

• A/California/7/2009(H1N1)-like virus,

• A/Victoria/361/2011(H3N2)-like virus,

• B/Wisconsin/1/2010-like virus.

Since the A/H3N2 and the B virus strains were changed, a yearly licence clinical study have to be performed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: September 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult persons aged 18 to 59 years, elderly persons aged =60 years from both sexes, mentally competent;

• Are in good health (as determined by vital signs and existing medical condition) or are in stable medical condition. Subjects will not be excluded with known adequately treated clinically significant organ or systemic diseases (e.g. asthma or diabetes), such that, in the opinion of the investigator, the significance of the disease will not compromise the subject's participation in the study;

• Female volunteers aged 18-59 years (i.e. participants of childbearing potential) with a negative result from the urine pregnancy test prior to vaccination who agrees to use an acceptable contraception method or abstinence throughout the trial and not become pregnant for the duration of the study.

• Capability of participants to understand and comply with planned study procedures;

• Participants provide written informed consent prior to initiation of study procedures;

• Absence of existence of any exclusion criteria.

Exclusion Criteria:

• Pregnancy, breast feeding or positive urine pregnancy test at baseline prior to vaccination. Female subjects who are able to bear children but not willing to use an acceptable contraception method for the duration of the study.

• Known hypersensitivity to eggs, chicken protein, thiomersal, formaldehyde, gentamycin, ciprofloxacin, neomycin, vancomycin or any other component of the vaccine;

• History of Guillain-Barré syndrome;

• History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine;

• Serious disease, such as cancer, autoimmune disease, advanced arteriosclerotic disease, complicated diabetes mellitus, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure;

• Immunosuppressive therapy within 36 months prior to vaccination;

• Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids;

• Receipt of immunostimulants;

• Receipt of parenteral immunoglobulin, blood products and/or plasma derivate within 3 months prior to vaccination;

• Suspected or known HIV, HBV or HCV infection;

• Acute disease and/or axillary temperature =37oC within 3 days prior to vaccination;

• Vaccine therapy within 4 weeks prior to vaccination;

• Influenza vaccination (any kind) within 6 months prior to vaccination;

• Experimental drug therapy within 4 weeks prior to vaccination;

• Concomitant participation in another clinical study;

• Any condition which, in the opinion of the investigator, may interfere with the evaluation of the study;

• Past or current psychiatric disease of the volunteer that upon judgement of the investigator may have effect on the objective decision-making of the volunteer;

• Alcohol or drug abuse of the participant.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Drug:
• Fluval AB vaccination
Vaccination with Fluval AB suspension for injection

Locations

Country	Name	City	State
Hungary	District Doctor's Office	Budapest
Hungary	District Doctor's Office	Pilisvörösvar
Hungary	District Doctor's Office	Szentendre

Sponsors (1)

Lead Sponsor	Collaborator
Omninvest Vaccine Manufacturing, Researching and Trading Ltd.

Country where clinical trial is conducted

Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of immunogenicity measures in comparison to criteria specified in CPMP/BWP/214/96	To assess immunogenicity of a single intramuscular injection of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 µgHA/0.5mL of seasonal A/H1N1, A/H3N2 and B influenza antigens each), as measured by haemagglutination inhibition (HI) test in comparison to criteria specified in CPMP/BWP/214/96.	21-28 days after immunization	No
Secondary	To evaluate safety and tolerability (incidence of adverse events) of a single intramuscular injection of Fluval AB suspension for injection.	Safety and tolerability will be assessed in comparison to available safety and tolerability data on Fluval AB suspension for injection: number and percentage of subjects with at least one local reaction between Day 0 and Day 21-28.; number and percentage of subjects with at least one systemic reaction between Day 0 and Day 21-28.; number and percentage of subjects with at least one adverse reaction between Day 0 and Day 21-28.	From Day 0 until 21-28 days after immunization	Yes